Electrocore ECOR 深 沪
已收盘 09-11 16:00:00 美东时间
9.62
+0.430
+4.68%
华盛通- 最 高9.99
- 今 开9.185
- 成交量 4.02万股
- 最 低 9.185
- 昨 收 9.19
- 总市值 8673.28万
- 52周最高 10.95
- 市盈率 静 --
- 换手率 0.45%
- 52周最低 4.41
- 委 比 33.11%
- 总股本 901.59万
- 历史最高 303.75
- 量 比 1.06
- 振 幅 8.76%
- 历史最低 2.925
- 每 手 1
- 风险率 1.63%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多electroCore to Participate at H.C. Wainwright Global Investment Conference
electroCore, Inc. announced that its management will participate in the H.C. Wainwright 28th Annual Global Investment Conference at the Lotte New York Palace Hotel on September 15, 2026. Joshua Lev, Co-CEO, President, and CFO, will engage in a fireside chat and host investor meetings. Investors can request meetings via their H.C. Wainwright sales representative or contact electroCore Investor Relations at investors@electrocore.com. The company sp...
09-10 12:00
electroCore Appoints Joshua Lev, Mike Fox As Co-CEOs, Effective Sept. 8
electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company and leader in non-invasive vagus nerve stimulation technologies, today announced that it has appointed Joshua Lev and Mike Fox as Co-Chief Executive Officers and members of the Board of Directors, effecti...
09-09 20:01
electroCore, Inc. Appoints Joshua Lev and Mike Fox as Co-Chief Executive Officers
electroCore, Inc. has appointed Joshua Lev and Mike Fox as Co-Chief Executive Officers, effective September 8, 2026. The decision reflects the company's confidence in their complementary strengths, experience, and leadership capabilities to enhance shareholder value. Lev brings strategic vision, financial expertise, and public markets experience, while Fox offers market development and commercial leadership skills. Together, they will lead the co...
09-09 12:00
electroCore’s Truvaga® Named Best Luxury Biohacking & Longevity Brand in the USA by Luxury Lifestyle Awards
Truvaga, a non-invasive vagus nerve stimulation (nVNS) wellness brand by electroCore, Inc., has been named the 2026 Best Luxury Biohacking & Longevity Brand in the USA by Luxury Lifestyle Awards. The award recognizes Truvaga for its patented technology, thoughtful design, and personalized wellness experience. The brand offers handheld devices that provide two-minute sessions to support relaxation, stress management, sleep quality, focus, and over...
08-25 12:00
electroCore Lowers FY2026 Sales Guidance from $41.642M to $41.600M vs $41.921M Est
electroCore (NASDAQ:ECOR) lowers FY2026 sales outlook from $41.642 million to $41.600 million vs $41.921 million estimate.
08-07 04:23
electroCore 2026年第二季度财报：营收增长28%，净亏损收窄
electroCore 2026年第二季度营收945万美元，同比增长28%；每股亏损由0.44美元收窄至0.33美元，调整后EBITDA亏损改善26%，全年收入增长指引上调至超过30%。
08-07 01:42
electroCore to Participate in Upcoming Investor Conferences
electroCore, Inc. announced that its management will participate in two investor conferences: the Needham 11th Annual Virtual MedTech and Diagnostics Conference on August 11, 2026, and the Canaccord Genuity 46th Annual Growth Conference in Boston on August 11-12, 2026. Management will host one-on-one meetings and present at these events. Investors can request meetings via their sales representatives or contact electroCore Investor Relations at in...
08-03 12:00
electroCore to Announce Second Quarter June 30, 2026, Financial Results on Thursday, August 6, 2026
electroCore, Inc. announced it will report second-quarter 2026 financial results after market close on August 6, 2026. A webinar at 4:30 PM EDT will review the results and answer questions. Investors can join via dial-in (646) 931-3860 or the registration link provided. The company specializes in bioelectronic technologies for health and wellness, with products like gammaCore® and Quell® for chronic pain treatment, and Truvaga™ and TAC-STIM™ for ...
07-30 12:00
New Review Examines Anatomical and Methodological Differences Between Auricular and Cervical Vagus Nerve Stimulation
electroCore, Inc. announced the publication of a peer-reviewed review article in *Frontiers in Neuroscience* comparing transcutaneous auricular vagus nerve stimulation (taVNS) and transcutaneous cervical vagus nerve stimulation (tcVNS). The article, authored by Peter S. Staats, MD, MBA, and Justyna Blake, explores the anatomical, physiological, and clinical differences between the two approaches, highlighting tcVNS as a clinically validated metho...
07-16 12:00
